Alzheimer's disease (AD), the most common form of dementia, is rapidly becoming a major global health concern among the elderly. Multiple pathogenic components and abnormalities in the behavior of various cell types within the CNS play a role in AD pathogenesis. The most well-studied form of neurodegenerative amyloidopathy is Alzheimer's disease (AD). Molecular pathology, aided by genomes and proteomics, is improving our understanding of neurodegenerative disease development, diagnosis, and treatment. The goal of molecular pathology is to uncover disease mechanisms by identifying molecular and pathway changes. The use of old and novel tools established in biochemistry, cell biology, molecular biology, proteomics, and genetics to the evaluation of pathological processes is at the heart of this still-evolving science. The value of molecular pathology as a supplement to histopathology in nonclinical drug development is well understood in the pharmaceutical industry.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : Neuroimaging-based evaluation of scalp acupuncture for neural repair and reorganization in children with cerebral palsy
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : The Bansal neuron model: A nonlinear framework for exploring neuronal excitability and electrophysiological dysfunction in Alzheimer's disease
Abhishek Bansal, New Era Consultancy Services, India
Title : Neurophysiological change and cognitive response to levetiracetam in Alzheimer disease: Testing the missing mechanistic link
Christopher Hubler, Emergent Neural Systems Institute for Research, United States